Pathway candidateNCBI-verifiedprotein-coding

KMT2A

lysine methyltransferase 2A

NCBI Gene: 4297 Ensembl GeneCards UniProt: Q03164

Pathway candidate — not linked to PFS or PSSD by any record here

KMT2A is in the library because it belongs to the epigenetic regulation family. No study, report or commentary in the corpus names it, so a variant in KMT2A is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 11 (epigenetic regulation). Encodes a transcriptional coactivator that plays an essential role in regulating gene expression during early development and hematopoiesis. The protein contains multiple conserved functional domains.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Histone-lysine N-methyltransferase 2A
Function (excerpt): Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). Catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'.
Subcellular location: Nucleus.
Tissue specificity: Heart, lung, brain and T- and B-lymphocytes.
Associated conditions: Wiedemann-Steiner syndrome (WDSTS).

Source: UniProtKB/Swiss-Prot Q03164, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Epigenetic persistence is the leading hypothesis for why post-drug syndromes endure after the drug is gone; chromatin regulators are therefore priority candidates in any persistence mechanism.

Written for the whole epigenetic regulation family, not for KMT2A specifically.

Mentioned in 0 corpus records

No corpus record names KMT2A directly yet. It is in the library because it sits in a pathway the corpus tracks (Epigenetic regulation).

Also in epigenetic regulation

All 130 genes

Browse by family on the gene families page.

Gene summary

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Histone-lysine N-methyltransferase 2A
Function (excerpt): Histone methyltransferase that plays an essential role in early development and hematopoiesis. Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac). Catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place. Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity. Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9'.
Subcellular location: Nucleus.
Tissue specificity: Heart, lung, brain and T- and B-lymphocytes.
Associated conditions: Wiedemann-Steiner syndrome (WDSTS).